Physical and microbiological stability of an extemporaneous tacrolimus suspension for paediatric use

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 2, 2006, Pages 167-172

  Han, J ^a,b,c,d   Beeton, A ^a,b,c   Long, P F ^a,b,c   Wong, I ^a,b,c   Tuleu, C ^a,b,c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d KEELE UNIVERSITY   (United Kingdom)

Author keywords

Extemporaneous; Formulation; Paediatric; Stability; Suspension; Tacrolimus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; ORA PLUS; TSUKUBAENOLIDE;

ARTICLE; BACTERIUM CONTAMINATION; CHILD; COLONY FORMING UNIT; DRUG CAPSULE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; FUNGUS CULTURE; GOOD MANUFACTURING PRACTICE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LASER DIFFRACTION; MICROBIOLOGICAL EXAMINATION; MICROSCOPY; PARTICLE SIZE; PHYSICAL PARAMETERS; SUSPENSION; SYRUP;

EID: 33645472113     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00720.x     Document Type: Article

References (16)

1. Jacobson PA Johnson CE West NJ Foster JA 1997 Stability of tacrolimus in an extemporaneously compounded oral liquid American Journal of Health-System Pharmacy 54 178 180
2. Yamashita K Nakate T Okimoto K et al. 2003 Establishment of new preparation method for solid dispersion formulation of tacrolimus International Journal of Pharmaceutics 267 79 91
3. Reding R Sokal E Paul K et al. 2002 Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients Pediatric Transplantation 6 124 126
4. Van Mourik IDM Holder G Beath S McKiernan PUB Kelly D 1999 Increased risk of acute graft rejection in paediatric liver transplant recipients on tacrolimus suspension 3rd International Congress on Immunosuppression San Diego, CA
5. Anglicheau D Legendre C Thervet E 2004 Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives Transplantation 78 311 315
6. Ansel HC Allen LV Popovich NG 1999 Pharmaceutical dosage forms and drug delivery systems New York Lippincot Williams & Wilkins
7. Ofner CM Schnaare RL Schwartz JB 1996 Oral aqueous suspensions In Lieberman HA Rieger MM Banker GS eds Pharmaceutical dosage forms - disperse systems Vol. 2 New York Marcel Dekker, Inc. 149 181
8. Nash RA 1996 Pharmaceutical suspensions In Lieberman HA Rieger MM Banker GS eds Pharmaceutical dosage forms - disperse systems Vol. 2 New York Marcel Dekker, Inc. 1 46
9. Syroeshkin AV Popov PI Grebennikova TV Frolov VA Pleteneva TV 2005 Laser diffraction for standardization of heterogeneous pharmaceutical preparations Journal of Pharmaceutical and Biomedical Analysis 37 927 930
10. Washington C 1992 Particle size analysis in pharmaceutics and other industries New York Ellis Horwood Limited
11. International Organization for Standardization 1999 Particle size analysis - laser diffraction mehtods. Part 1: gerneral principles Standard no. ISO 13320-1 Geneva, Switzerland ISO
12. Hunter RJ 1986 Foundations of colloid science New York Oxford University Press
13. Han JH Davis SS Washington C 2001 Physical properties and stability of two emulsion formulations of propofol International Journal of Pharmaceutics 215 207 220
14. Han J Davis SS Papandreou C Melia C Washington C 2004 Design and evaluation of an emulsion vehicle for paclitaxel. I. Physicochemical properties and plasma stability Pharmaceutical Research 21 1573 1580
15. Driscoll DF Etzler F Barber TA Nehne J Niemann W Bistrian BR 2001 Physicochemical assessments of parenteral lipid emulsions: light obscuration versus laser diffraction International Journal of Pharmaceutics 219 21 37
16. Arndt C Cruz M Cardenas M Heitman J 1999 Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans Microbiology 145 1989 2000